ENTtoday
  • Home
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Multimedia
    • Video
    • Audio
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Biologics for Chronic Rhinosinusitis and Nasal Polyposis

by Elizabeth Hofheinz, MPH, MEd • June 9, 2019

  • Tweet
  • Email
Print-Friendly Version
Interleukin 4 (IL-4) binds to its receptor.

Interleukin 4 (IL-4) binds to its receptor.
© Juan Gaertner / shutterstock.com

The possibility of utilizing biologic therapies for chronic rhinosinusitis (CRS), an inflammatory condition of the sinonasal mucosa, is a growing area of interest and research. This rise in interest is due in part to the success of biologics in treating other inflammatory conditions such as asthma and atopic dermatitis. A panel of experts gathered at the Triological Society Annual Meeting discussed the biologics that are being explored for CRS and nasal polyposis.

You Might Also Like

  • Are New Biologics a Game Changer for Treating Nasal Polyposis?
  • Do Preoperative Corticosteroids Benefit Patients with Chronic Rhinosinusitis with Nasal Polyposis?
  • What Is the Role of Nasal Endoscopy in the Diagnosis of Chronic Rhinosinusitis?
  • Tips for Treating Chronic Rhinosinusitis with Nasal Irrigation
Explore This Issue
June 2019

Jean Kim, MD, PhD, an associate professor of otolaryngology–head and neck surgery at Johns Hopkins University School of Medicine in Baltimore and panel moderator, said, “What makes antibodies so attractive is the specificity for the target. However, there are some previously reported uncommon nonspecific effects that may be detrimental, such as immunosuppression, cardiomyopathy, new cancer, and cytokine storm. Additionally, autoantibodies and allergy to the antibodies have also been reported.”

What is known about the biology of nasal polyps (NP) comes from understanding similarities with asthma, he said. In fact, he added, the rationale for NP drug development originates from studies of severe asthma. Both display similar patterns of Th2 (or type 2) inflammation. Their behavior is also similar, with both displaying a responsiveness to steroids. Thus, the targets that mediate Th2 inflammation are the biologic drug targets that are being developed for nasal polyposis, which include IgE, IL5, IL4, and IL13.

Dupilumab

Joseph K. Han, MD, director of the division of rhinology and endoscopic sinus and skull base surgery and medical director of the division of allergy at Eastern Virginia Medical School in Norfolk, and his colleagues recently completed a phase 3 trial on the use of dupilumab, which blocks IL-4 and IL-13, for nasal polyposis. This medication received priority review by the FDA, and full approval would make it the first biologic approved by the FDA to treat CRS with NP (CRSwNP), he said.

His study, which involved 276 patients, concluded that dupilumab is safe and effective for CRSwNP. Patients treated with this drug showed progress in as early as four weeks and experienced a reduction in the size of polyps, the severity of nasal congestion, and the need for surgery or steroids, said Dr. Han. These improvements continued through week 24, and the need for surgery in these patients was reduced by 73%.

The two primary outcomes, nasal congestion and NP, were both statistically significant, he added. Regarding congestion specifically, those who had medium to severe congestion at the outset of the study had zero to mild congestion by the end of the study.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Features, Practice Focus, Rhinology Tagged With: biologic therapies, chronic rhinosinusitus, Nasal polyposis, nasal polyps, Triological Society Annual Meeting 2019Issue: June 2019

You Might Also Like:

  • Are New Biologics a Game Changer for Treating Nasal Polyposis?
  • Do Preoperative Corticosteroids Benefit Patients with Chronic Rhinosinusitis with Nasal Polyposis?
  • What Is the Role of Nasal Endoscopy in the Diagnosis of Chronic Rhinosinusitis?
  • Tips for Treating Chronic Rhinosinusitis with Nasal Irrigation

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Is There a Crisis in the Otolaryngology Match?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Vertigo in the Elderly: What Does It Mean?
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Post-Tonsillectomy Taste Disorders Rare but Present
    • Study: Artificial Intelligence Can Help Predict Risk of Thyroid Cancer on Ultrasound
    • Nobel Awards for Otolaryngology Research
    • Visual Abstract Competition to Launch at 2020 Triological Society Sections Meeting
    • More Severe OSA Leads to Higher Blood Pressure in Patients with Resistant Hypertension
    • Link Between Hearing and Cognition Begins Earlier Than Once Thought

Polls

Will registry information and data science improve patient care?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2019 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.